141 results about "Liver toxicity" patented technology

The instant invention provides for novel catiomc lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids comprising at least one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The invention discloses yacon ice cream and a manufacturing method thereof, wherein, the yacon ice cream comprises whole milk powders accounting for 12 to 15 percent, unsweetened evaporated milk accounting for 6 to 9 percent, cream accounting for 7 to 9 percent, white granulated sugar accounting for 3 to 4 percent, starch syrup accounting for 1 to 1.5 percent, sodium alginate accounting for 0.15 to 0.2 percent, monoglyceride accounting for 0.15 to 0.2 percent, yacon granules accounting for 20 to 25 percent and appropriate drinking water. The manufacturing method of the yacon ice cream comprises the steps of yacon granule preparation, raw material mixing preparation, sterilization, homogenizing, cooling, ageing, congealing, filling, rigidification and the like; the yacon ice cream contains yacon granules, achieves cool and delicious taste, achieves double functions of nourishment and health care, and further achieves the nourishment and health care effects of reducing temperature, relieving summer-heat, clearing intestines and stomach, resolving liver toxicity, reducing blood fat, reducing blood pressure, helping digestion, preventing oxidation, preventing constipation and the like compared with the traditional ice cream.

Nanoparticulate compositions comprising a corticosteroid and a leukotriene receptor antagonist are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining a leukotriene receptor antagonist with a corticosteroid in a particle size ranges of less than 2000 nm in a single formulation results in improved efficacy. In addition, patient compliance is enhanced since only one dosage form is needed. Furthermore, local administration of the leukotriene receptor antagonist results in less liver toxicity since the liver will be exposed to lower amounts of drug than happens following oral administration. The drug compositions according to the invention can be formulated into inhalation, nasal, or ocular formulations.

Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain coupled with inclusion of hydrolysable functionality in the lipid chains to enhance the efficiency and tolerability of in vivo delivery of siRNA.

The invention relates to the use of fibrates for lowering the liver toxicity of MTP inhibitors as well as pharmaceutical compositions containing an MTP inhibitor and a fibrate.

This disclosure relates to methods for improving the therapeutic index of a chemotherapeutic drug in the treatment of patients afflicted with cancer, including, for example, reducing chemotherapy-related toxicity (e.g., liver toxicity).

Formula (I) compounds are described: Where the groups are as defined here below, and their use as medinies, particularly as serum glucose and serum lipid lowering agents. Said medicines are useful for the prophylaxis and treatment of diabetes, particularly type 2, and its complications, Syndrome X, the various forms of insulin resistance, and hyperlipidaemias, and present reduced side effects, and, particularly, reduced or no liver toxicity.

The invention belongs to the field of animal experiment models, and discloses application of a composite high-fat forage to construct a non-alcoholic fatty liver disease rat model. The high-fat forage is composed of the following raw materials in percent by mass: 77.5% of a rat basic forage, 10% of egg, 10% of coconut oil, 2% of cholesterol, 0.5% of bile salt, and 500mg / kg / d of sodium valproate calculated according to the rat weight. After 8 weeks, rats all have typical non-alcoholic fatty live symptoms, and liver has a lot of fat accumulation along with inflammatory cell infiltration. The model establishing time is short, the success rate is high, and the composite high-fat forage is applicable to pathogenesis research induced by high-fat-diet combined medicines with liver-toxicity side effect, screening of related control measures and efficacy evaluation of treatment medicines.

Methods and compositions for the stabilization of aminotransferase activity of plasma or serum are provided. Such methods will be useful in the accurate determination of tests associated with liver toxicity.

The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. The invention also relates to methods of reducing the likelihood of a patient at risk for non-alcoholic fatty liver diseases (NAFLD), including non-alcoholic steatohepatitis (NASH), or treating NAFLD or NASH including primary NASH, NASH secondary to liver transplantation (NASH post-liver transplantation) or cirrhosis represent alternative aspects of the present invention.

Biomarker signatures were identified which can be used to diagnose or predict kidney or liver toxicity and more specifically renal tubular toxicity as a consequence of disease or drug treatment.

The invention belongs to the technical field of medicine, particularly relates to a Chinese medicinal composition for treating cerebral thrombosis and a preparation method thereof, and aims to overcome the defects of high liver toxicity and poor curative effect of the conventional chemical treatment medicament for treating cerebral thrombosis in the prior art. The Chinese medicinal composition for treating or preventing cerebral thrombosis provided by the invention comprises 10-50 parts of peach seed, 10-20 parts of notopterygium root, 5-20 parts of sophora flower, 5-15 parts of paniculate swallowwort root, 5-10 parts of prepared rehmannia rhizome, 5-15 parts of lily, 5-15 parts of honeysuckle flower, 1-10 parts of red-rooted salvia root, 5-15 parts of barbary wolfberry, 9-15 parts of Indian buead, 9-15 parts of Szechuan lovage rhizome, 5-15 parts of dahurian angelica root, 0.2-9 parts of berberine, 5.5-15 parts of white paeony root, 6-9 parts of rhodiola rosea and 10-15 parts of liquoric root. The Chinese medicinal composition has a very good treatment or prevention effect on cerebral thrombosis, and has a low medicinal side effect and remarkable clinical popularization value.

The present invention relates to pharmaceutical compositions for reducing essential hypertension and systemic inflammation. While many drugs have been found to treat hypertension, the currently available drugs often do not maintain reduced blood pressure at the preferred norm of 115 / 75 mm Hg or less throughout a 24 hour period. The current invention provides compositions comprising at least one hypertensive drug combined with the natural product Coenzyme Q10 (ubiquinone or CoQ10), which synergizes with the antihypertensive drugs to maintain low blood pressure throughout the day and night while generating other positive effects on the risks of cardiovascular disease, renal failure, and stroke. CoQ10 also counteracts some of the side effects of some hypertensive drugs such as tiredness, weakness, and / or liver toxicity. The invention further describes therapeutically effective methods for reducing systemic inflammation in hypertensive mammals comprising treatment with an antihypertensive composition that includes at least one angiotensin-converting enzyme inhibitor or angiotensin receptor blocker and CoQ10 (ubiquinone). The invention metrics for reducing systemic inflammation comprise the reduction of serum levels of high sensitivity C-reactive protein (CRP), Interleukin 6 (IL-6), and / or tumor necrosis factor-alpha (TNF-alpha). These antihypertensive-CoQ10 combinations will synergistically reduce both hypertension and systemic inflammation.

The invention provides healthcare Puer tea with the function of anti-HIV and improving the immunity. The healthcare Puer tea comprises the components with the following mass ratio: 30 to 50 percent of Puer tea, 10 to 20 percent of dendrobium, 10 to 20 percent of ginseng, 5 to 10 percent of tuckahoe, 10 to 20 percent of rhizoma gastrodiae and 8 to 18 percent of lucid ganoderma. The tea is post-fermentation tea, in the process of fermentation, in addition to the nutrient solution of biological enzyme is added, the fungal substance including Lucid Ganoderma and Rhizoma Gastrodiae as well as the medicine with refreshing and invigorating qi is added. Besides of the function of alleviating the damage on the immune cell, promoting the restore of the impaired immune cell, adjusting the absorption environment of intestinal tract and improving the immune system of human body and the gastrointestinal absorption, the invention has the important function of the strong inhibition role on AIDS virus i.e. HIV. Based on the clinical observation, the invention can reduce the occurrence rates of toxic and the side effects caused by the anti-medicine taken by patients, especially the gastrointestinal symptoms and the liver toxicity, promote the medication compliance of patients, significantly increase the number of human CD4 immune cells, do not has the toxic and side effects, thereby promoting the efficacy of anti-virus therapy.

Methods and compositions useful for preventing the disruption of thiol (sulfur) signaling which affects degenerative / age related disease and other disease states related to thiol redox signaling, such as S-glutathiolation. The compositions are capable of increasing the DNA transcription of Gamma-Glutamyl-cysteine synthase which is the rate limiting enzyme for the production of the thiol regulating enzyme Glutathione. The acid-stable compositions disclosed herein contain esterfied and free form cafestol and kahweol, and may be formed using ground roasted or unroasted coffee beans. The beans in combination with water are exposed to cavatonic energy sonic or mechanical. C&K typically increase cholesterol and damage the liver. The compositions disclosed are absorbed before or after the distal portion of the small intestines, eliminating liver toxicity and increases in cholesterol. Additional materials may be added to the compositions, such as additional hydrophobic compounds hydrophilic compounds, and may be added to the film or embedded in the compositions by the cavitation process. The process is also adapted for use in all standard methods of brewing coffee, causing the coffee to possess the disclosed compositions.

Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

The invention discloses a liver organ model and a construction method and application thereof. The method includes steps: (1) subjecting embryonic stem cells to supported culture; (2) preparing cell balls, sequentially subjecting to differentiation culture through a mesoblast-entoderm stage, a liver induction stage and a mature stage to obtain different types of cells including liver cells, bile duct cells and endothelial cells, and subjecting the different types of cells to orderly arrangement and combination to form a liver organ. By control of exposure time of compounds in different differentiation stages, screening and evaluation of liver toxicity effects and liver early development influences of the compounds are carried out. In addition, by the liver organ model, high-flux short-timeevaluation of the liver development influences and the liver toxicity effects of one compound or various compounds can be realized, evaluation indexes are simple, direct and diversified, quick primary screening of a great quantity of new synthetic compounds can be realized, and a foundation is laid for subsequent compound modification, pharmacological and toxicological mechanism research or marketing for use.

The invention discloses a metabonomics-based application of endogenous small-molecular substances in rapid detection of hepatotoxicity. The endogenous small-molecular substances are 12 hepatotoxicity biomarkers, i.e., L-alanine, L-phenylalanine, L-carnitine, L-carnitine palmitoyl, tryptophan, arachidonate, cholic acid, lysophosphatidylcholine (14:0), lysophosphatidylcholine (16:1), lysophosphatidylcholine (18:2), lysophosphatidylcholine (20: 3) and hemolysis phosphatidyl ethanolamine (18:2); and the endogenous small-molecular substances also refers to 3 special hepatotoxicity biomarkers, i.e. L-carnitine, cholic acid and lysophosphatidylcholine (14:0). By adopting the hepatotoxicity biomarkers, the discovery and diagnosis of the liver injury can be earlier than those of the existing biochemical detection indexes, the hepatotoxicity biomarkers can be well used for preventing, discovering and treating the hepatotoxicity, the limitation of the existing indexes can be overcome, and accurate detection information can be provided in time.

The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatic stellate phenotype and cells that express a hepatic sinusoidal endothelial phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.

The invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express hepatocyte phenotypes and hepatocyte progenitor phenotypes. More particularly, the invention relates to methods for culturing cells so that the cells are induced to differentiate into cells that express a definitive endodermal phenotype, a liver-committed endodermal phenotype, a hepatoblast phenotype, and hepatocyte phenotype. The invention is also directed to cells produced by the methods of the invention. The cells are useful, among other things, for treatment of liver deficiency, liver metabolism studies, and liver toxicity studies.

The invention belongs to the fields of genetic engineering and oncology, and discloses an SNP marker related to liver toxicity of platinum type chemotherapeutic medicines and applications thereof. The marker is a composition of rs6681909, rs4140932, rs13131227, rs4446279, rs17053350, rs9402873, rs16878272, rs13267737, rs7008590, rs947853, rs2838566, rs1383888, rs9642723, rs3822296, rs2160046, rs10002931, rs10032941, rs6449138, rs1048037 and rs10086636. The marker and primer probes thereof can be used for preparing a diagnosis kit of the liver toxicity of platinum type chemotherapeutic medicines, and are good in sensitivity and specificity.

The invention relates to a method for rapidly evaluating the damage effect on the hepatic function of zebra fishes by compounds. The method includes the steps that 1, fertilized normal zebra fish embryos are moved into breeding holes; 2, continuous chemical hatching is performed on the zebra fish embryos in the breeding holes, and the zebra fish embryos are marked to be a compound set to be detected; 3, livers of the zebra fish embryos are observed, and the liver area of the zebra fish embryos and the area of zebra fish embryo bodies are recorded and calculated; 4, according to the range relation between the index of the liver area of the zebra fish embryos of the compound set to be detected and the index of the liver area of normal zebra fish embryos, whether the compound set to be detected has liver toxicity is judged. The index of the liver area is used as a detection index for evaluating the hepatic function of the zebra fishes for the first time, and therefore the method is more scientific and objective and improves the accuracy of results. An established model for evaluating the damage effect on the hepatic function of the zebra fishes by the compounds has the advantages of being easy to manufacture, rapid to use, stable, reliable and good in repeatability.